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Treatment gapThis study, supported by the RwandanMinistry of Health and theWorld Health Organization, was conducted in
2005 to determine the prevalence of epilepsy and its sociocultural perception in Rwanda, as well as epilepsy-
related knowledge and practices of health-care professionals (HCPs). A cross-sectional, nationally representative
surveywas conducted throughout Rwanda by trained investigators. Participants were recruited by random clus-
ter sampling based on the organization of administrative units in the country. Overall, 1137 individuals (62% from
rural areas)were interviewed. The prevalence of epilepsywas estimated to be 49 per 1000 people or 41 per 1000
for active epilepsy. Onset of epilepsy before the age of 2 years was reported in 32% of the cases. Family history of
epilepsy, head trauma, and premature delivery were reported in 53%, 50%, and 68% of the cases, respectively.
Most (68%) patients did not receive any medical treatment for epilepsy; 21.5% had received some form of tradi-
tional treatment. According to responses from the general population, people with epilepsy should not be enti-
tled to schooling (according to 66%), to work (according to 72%), to the use of public places (according to
69%), or to marriage (according to 66%). Furthermore, 50% believed that epilepsy was untreatable, and 40%
thought that it was transmissible. Of the 29 HCPs interviewed, the majority knew the deﬁnition of epilepsy
and status epilepticus, as well as basic treatment options and side effects. However, 90% believed that
treatment was only necessary in the ﬁrst week after a seizure. Living with epilepsy was associated heavily
with stigma, and a signiﬁcant treatment gap (68%) was identiﬁed. Following this study, numerous actions
have been taken by the Rwandan government, the Rwandan League Against Epilepsy, and several nongovern-
mental organizations to increase awareness about epilepsy and to close the treatment gap. An overview of
these activities is provided.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epilepsy is a common neurological condition worldwide; however,
the incidence, the prevalence, and the burden associated with the dis-
ease are highest in low-income countries. Of the estimated 70 million
people livingwith epilepsy globally, 80% are in developing countries [1].
In recent years, a number of studies have reported data on the
prevalence of epilepsy in Sub-Saharan Africa, as well as on risk factors
and the treatment gap. Up to 2004, epidemiological data on epilepsy
in the Central African country of Rwanda were sparse. Rwanda is a
landlocked country with an area of 26,338 km2 and a population of
approximately 12 million inhabitants [2]. In 2005, the prevalence ofue Caraes Ndera, BP 423 Kigali,
. This is an open access article underepilepsy in this country was reported to be 7 per 1000 [3]. This estimate
was obtained from a survey on the prevalence and causes of musculo-
skeletal impairment; questions about seizures were included at the
request of Ministry of Health, since people with epilepsy often came
to the attention of health services through treatment for trauma caused
during seizures.
Our study, whichwas supported by the RwandanMinistry of Health
and theWorld Health Organization, ran almost concurrently to the one
described above; however, its focus was exclusively on epilepsy.
Furthermore, while the primary objective was to determine the preva-
lence of epilepsy in Rwanda, our study had several further objectives.
Notably, we sought to identify the etiological factors of epilepsy in
Rwanda and to evaluate the sociocultural perception and the level of
knowledge and attitudes about epilepsy in the general population. We
also assessed the level of knowledge and practices of health-care
professionals (HCPs) caring for people with epilepsy.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in developing a comprehensive program to increase awareness of
epilepsy, to reduce the stigma associated with the disease, and to
close the treatment gap. We provide the results of the cross-sectional
survey, as well as an overview of the numerous actions taken by the
Rwandan government, the Rwandan League Against Epilepsy, and sev-
eral nongovernmental organizations since 2005 as the direct conse-
quence of this survey.
2. Methods
This was a cross-sectional study conducted in September 2005
under the auspices of the Rwandan Ministry of Health in collaboration
with theWorld Health Organization (WHO). Participation in the survey
was entirely voluntary and anonymous. All investigators carried an
authorization letter from the Ministry of Health, which also included
an explanation of the rationale and the objectives of the survey.
The study consisted of three separate surveys. The ﬁrst two surveys
were conducted in the general population — the ﬁrst one was used to
determine the prevalence of epilepsy, and the second one was used to
evaluate the sociocultural perception and the level of knowledge
about epilepsy. The third survey, conducted among HCPs, assessed
their level of knowledge and practices relating to epilepsy.
2.1. Population and health-care professional sampling
The size of the sample from the general population was calculated
based on the estimated 10 per 1000 expected prevalence of epilepsy,
with an accuracy of 2.5% for an inﬁnite population and a conﬁdence
level of 95%, taking into account a cluster 2 effect. The sample size
needed for this survey was calculated to be 1137 people.
Survey locations were determined by random cluster sampling.
Clusters were selected in three stages based on the units of administra-
tive structures in Rwanda. In the ﬁrst step, ﬁve administrative districts –
one from each of the ﬁve provinces of the country (North, East, West,
South, and City of Kigali) – were selected randomly. In the second
step, ﬁve sectors – one from each of the ﬁve aforementioned adminis-
trative districts – were selected randomly. In the third step, 10 cells,
two from each of the sectors, were selected randomly. Each cell consists
of 110 households; consequently, with an average number of 4–5 peo-
ple in a typical household and 1100 households targeted, the ﬁnal num-
ber of possible inhabitants that could be reached was 4950.
Health-care professionals working in health centers serving in the
districts where the population-based survey was conducted were
randomly selected for participation in the survey. Seven such centers
were targeted.
2.2. Investigators and questionnaires
All survey investigators (at least senior technician in Health
Sciences) underwent speciﬁc training in epilepsy and the questionnaire
overseen by the project researcher (F. Sebera) and representatives of
the Ministry of Health and WHO.
The survey on the prevalence of epilepsy was conducted using a
validated questionnaire for countries in tropical and subtropical areas
developed by the Institute of Epidemiology and Tropical Neurology
of Limoges, the Pan African Association of Neurological Sciences
(PAANS), and the International League Against Epilepsy (ILAE) [4].
Brieﬂy, the questionnaire consists of nine modules or chapters and is
conducted in two stages. In the ﬁrst stage, the entire survey population
is screened using the ﬁrst two modules (demographics and screening)
in a door-to-door survey. In the second stage, all individuals screened
as positive are examined by a physician to conﬁrm epilepsy using the
third module (epilepsy conﬁrmation). If the individual was determined
to have epilepsy by the physician, as well as depending on the speciﬁc
objectives of the survey, the physician will ﬁll out the six remainingmodules (natural history of epilepsy, history of epilepsy, clinical exam-
ination, supplementary examination, etiologies and, antiepileptic
treatment).
The second part of the current survey, relating to the perception of
epilepsy in the general population, was carried out using a question-
naire developed by a team of clinical neurologists in Dakar, Senegal.
The questionnaire consists of three parts: general knowledge about
epilepsy, the experience of the population with epilepsy, and sociocul-
tural implications of epilepsy. The questionnaire used for HCPs was
developed by the ILAE and the International Bureau for Epilepsy (IBE)
and consists of multiple choice questions relating to epilepsy training,
clinical knowledge about epilepsy, and how people with epilepsy are
treated and supported.
All questionnaires were translated into Kinyarwanda and were
adapted to the sociocultural context of Rwanda.
2.3. Data collection, entry, and analysis
The general population survey was conducted in two phases. The
ﬁrst phase was a pilot, conducted in a single cell (Nonko) in the City
of Kigali. Following this, the investigators and project researchers met
to review and systematically rectify problems encountered during the
presurvey. The second phase involved the actual collection of data
through door-to-door visits of the households in the cells that had
been selected randomly. Only individuals with permanent residence
at the household were interviewed. If a given respondent was found
to screen positive based on the epilepsy questionnaire, they were
referred to a physician trained in epilepsy to conﬁrm the diagnosis.
The diagnosis of epilepsy was conﬁrmed following a detailed history
based on information provided by patients and their family, friends, or
caregivers and a full clinical examination.
Data were double entered and analyzed using SPSS software
(version 12.0). Chi-square tests were conducted to determine any
association between epilepsy and demographic variables.
3. Results
3.1. Prevalence of epilepsy
A total of 1137 individuals from the general population were
interviewed. Results from the randomly selected cells indicated that
all socioeconomic strata of the country were represented, with 38% of
the sample in urban areas and 62% in rural areas. Farmers and other ag-
ricultural workers accounted for just about half of the total population
(n = 576, 50.6%). The second largest group was composed of people
working from home and students or pupils (n = 212, 18.6%), followed
by unemployed (n = 177, 15.5%) and professionals (n = 169, 14.8%).
The mean age of those who were interviewed was 30.28 ± 16.2, and
52% were female.
Of the people interviewed, 71 had a positive response in the PAANS
screening questionnaire, in that they reported symptoms thatmay have
corresponded to a seizure. These symptoms included loss of conscious-
nesswith orwithout fall/convulsions; loss of urine and/or saliva; tremor
or uncontrollable movements of one part of the body without loss of
consciousness; auditory or visual hallucinations; and ‘strange’ bodily
feelings. Based on the positive results on the questionnaire, these indi-
vidualswere referred to a physician to conﬁrm the diagnosis of epilepsy.
Following detailed description of history and full clinical examina-
tion, ﬁfteen (21%) individuals were found to present these symptoms
in the context of concomitant diseases such as alcohol intoxication,
fever, stress/anxiety, diabetes, pregnancy complications, and malaria
and were, therefore, excluded. The remaining 56 (79%) individuals
had reported these symptoms more than once and did not have any
concomitant disease. Of these individuals, 42 reported that they had
already been diagnosed with epilepsy. Overall, of the 1137 individuals
in the survey population, 56 conﬁrmed cases of epilepsy were
Table 2
Reported age of patients at onset of epilepsy.
Age N (%)
≤2 years 20 (36%)
2–6 years 7 (13%)
6–12 years 9 (16%)
12–20 years 6 (11%)
≥20 years 11 (20%)
Unknown 3 (5%)
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dicated that 47 of the 56 individuals had active epilepsy, corresponding
to a prevalence of 41/1000. Having active epilepsy was deﬁned as hav-
ing experienced a seizure within 5 years before the survey.
With the exception of sex, a signiﬁcant association between demo-
graphic characteristics and cases of suspected epilepsy was identiﬁed
(Table 1). The highest cases of epilepsy were found among individuals
19 years of age or younger (12.6%), unemployed (12.4%), and single
(7.4%).
3.2. Seizure type and history
Of the people with epilepsy, the majority (84%) had experienced at
least one seizure during the last 5 years, and 14% reported having
experienced an episode of status epilepticus at least once.
The majority (70%) of seizures were described as generalized
tonic–clonic seizures based on detailed seizure history; however,
given limited diagnostic facilities, it could not be ascertained whether
these were primary or secondarily generalized seizures. Fourteen per-
cent of seizures were identiﬁed as secondarily generalized seizures. Of
the primary generalized seizures, 29% were determined as myoclonic,
29% as absence, 11% as atonic, and the remainder as unknown. Simple
partial seizures were reported by 16% of the people and complex partial
seizures by 14%. It is important to note that patients may have reported
more than one type of seizure. People with epilepsy were also asked if
they could identify speciﬁc factors that triggered their seizures. The
most frequently reported factors were emotion (18%), light stimuli
(18%), lack of sleep (14%), occurrence during sleep (13%), and upon
waking (11%).
A substantial proportion of the people with epilepsy (n = 20, 36%)
reported that the onset of their condition was before the age of 2 years
(Table 2). For the vast majority (95%) of the cases, onset of epilepsy
was at or before the age of 20 years.
3.3. Etiology
Based on patient history, the following factors were found to have
signiﬁcant association with epilepsy: consanguinity between parents;
family history of epilepsy; mother takingmedication during pregnancy;
premature birth; encephalitis; severe measles; neurological sequelae of
disease; contact with dogs, cats, and pigs; head trauma with loss of
consciousness (all p b 0.001); and prolonged posttraumatic comaTable 1
Distribution of epilepsy based on population demographics.
N Epilepsy cases
(%)
p-Value
Sex 0.401
Male 549 4.4
Female 587 5.5
Age b0.001
b19 years 273 12.6
20–49 years 719 2.5
≥50 years 145 2.7
Marital status b0.001
Married 606 1.8
Single 523 7.4
Length of stay in the region where the
survey was conducted
b0.05
b5 years 430 3.3
≥5 years 705 5.8
Profession b0.001
Professional 169 2.4
Agricultural worker/farmer 576 2.4
Home-based/student/pupil 212 7.5
Unemployed 177 12.4
Religion b0.05
Christian 1074 4.7
Other 51 11.8(p = 0.004). Overall, head trauma, family history of epilepsy, and pre-
mature birth were reported in 50%, 53%, and 68% of patients with
epilepsy, respectively. Family members with a history of epilepsy
mentioned most frequently were grandparents (5%), uncles and aunts
(17%), and cousins (21%).
Potential causes of epilepsy mentioned most frequently by respon-
dents were obstructed labor with fetal distress, serious childhood
illness, and head trauma. Themost common childhood diseases reported
by the respondents were meningitis, measles, and malaria, while head
trauma was most commonly reported as the consequence of road
accidents, blows to the head, and occupational accidents.
3.4. Treatment
Of the 56 people with epilepsy, 38 were not receiving treatment for
their condition, resulting in a treatment gap of 67.8% (Fig. 1). Fourteen
patients had been treatedwith traditionalmedicines,whichweremost-
ly of plant origin, but also included some of animal origin, minerals, and
amix. A total of 16 patients were on antiepileptic drugs (AEDs). Overall,
13 (23%) patients were receiving AEDs alone; of these, nine (16%) had
received AEDs from the very start of their treatment, while four (7%)
had started treatment with traditional options and then switched to
AEDs. Of the remaining patients, three (5%) were receiving a mix of
traditional medicine and AEDs, while the treatment history of two
patients was unknown.
Of the respondents who were receiving medical treatment in the
form of AEDs, only 49% managed to take the AEDs on a regular basis.
The main reasons for not taking AEDs regularly were lack of funds
(56%), unavailability of drugs (22%), personal reasons (11%), and
unknown (11%). The most frequently used AEDS were phenobarbital
(33%), valproic acid (44%), carbamazepine (44%), ethosuximide,
vigabatrin, and gabapentin (22%); respondents could report taking
more than one AED.
Among those who used traditional medicine, 82% had received their
treatment from a traditional healer, while the remainder had obtained
the treatment themselves. Most traditional medicines were adminis-
tered orally (84%); other routes of administration were dermal (6%)
and inhalation (3%). Scariﬁcation was also used as a method of
treatment by 3% and, ﬁnally, prayers or incantations by a further 3%.
Traditional treatmentwas considered effective by 48% of the respondents
who used them and by 65% of their family members.
3.5. Sociocultural perceptions of epilepsy in the general population
While themajority (84%) of respondents expressed a fear of epilepsy,
responses also revealed some understanding of the causes of epilepsy,
with 45% indicating that epilepsy was due to brain infection and 39%
reporting that it was the result of complications during childbirth.
However, a substantial proportion reported that epilepsy was also due
to evil spirits (53%), casting of an evil spell (32%), or evil thoughts
(28%). Respondents were allowed to indicate more than one cause.
Responses also revealed a deep stigma associated with epilepsy.
According to 66% of the respondents, people with epilepsy should not
be entitled to schooling (66%), to work (72%), to the use of public places
(69%), or to marriage (66%). Half the respondents also believed that
Fig. 1. Treatment pattern of patients with epilepsy in Rwanda in 2005.
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disease.
3.6. Epilepsy knowledge and practices of health-care professionals
Our study sample included 29 HCPs: 26 state nurses, two social
workers, and one senior technician in mental health. Most (86%) of
the respondents were familiar with epilepsy and status epilepticus, as
well as basic treatment options and their side effects. When asked to
describe the cause(s) of epilepsy, 41% reported that the most common
cause could not be detected, 38% cited brain tumor, and the remaining
21% reported that epilepsy was caused by a reduction in cerebral
blood ﬂow.
Respondents knew that antiepileptic treatment was not curative.
However, the majority (90%) believed that treatment was only neces-
sary in the ﬁrst week after a seizure; only 10% reported that treatment
was required for at least 2 years. Only 38% reported that urgentmedical
intervention was necessary if the duration of a seizure exceeds 15 min.
Of those, 90% chose phenobarbital as ﬁrst-line therapy in status
epilepticus, and 10% chose diazepam.
4. Discussion
4.1. Implications of the results — putting the ﬁndings in perspective
Based on the results of this cross-sectional survey, the prevalence of
epilepsy in Rwanda is estimated to be 49 per 1000 people, or 41 per
1000 if only active epilepsy is considered. Results also reveal a
treatment gap of 68%. However, it is important to note that the survey
was conducted in 2005 — should it be repeated today, the results will
most likely be different, especially the treatment gap.
The prevalence of 49 per 1000 people ranks among the highest in
Sub-Saharan Africa. In a review of 28 door-to-door studies published
between 1982 and 2004, a higher prevalence of epilepsy was reported
in only two countries [5]. Two studies conducted in Cameroon reported
estimates of 70 and 58 per 1000 in 1989 and 2000, respectively, and two
studies from Ivory Coast reported estimates of 74 and 59 per 1000 in
1990 and 1995, respectively [5]. A third study from Ivory Coast
conducted in 1988 reported a prevalence of only 7.6 per 1000, while a
recent study in Cameroon reported an even higher prevalence of 105
per 1000 [6]. However, the survey was conducted in a geographically
isolated area, hyperendemic for onchocerciasis. As noted by the reviewauthors, such divergence was also noted in two Nigerian studies
conducted among the same ethnic community living 20 km apart
using the same protocol; in one study, the prevalence was 5.3 per
1000, and, in the other, 37.0 per 1000 [5]. In another review of 32
studies conducted up to 2012, prevalence values ranging from 0 to 36
per 1000 were reported [7]. The large variation in the prevalence of ep-
ilepsy across Sub-SaharanAfrica is further demonstrated in a large-scale
study conducted across ﬁve countries: Kenya, South Africa, Uganda,
Tanzania, and Ghana [8]. The prevalence of active convulsive epilepsy
ranged from 7.0 per 1000 in South Africa to 14.8 per 1000 in Tanzania.
The investigators attributed this variation to the distribution and types
of risk factors rather than methodology since they had used the same
cross-sectional and case–control study design in all ﬁve countries.
The prevalence estimate in our survey was also substantially higher
than the 7 per 1000 reported in the only other survey conducted in
Rwanda [3]. However, as noted, there are several important differences
in the methodology of the two surveys. The primary focus of the survey
by Simms and colleagues was the prevalence and causes of musculo-
skeletal impairment. For detection of epilepsy, respondents who
answered ‘yes’ to any of the following during screening, “Do you ever
have ﬁts, involuntary movement, rigidity, or loss of consciousness?”,
were examined inmore detail by a physiotherapist using the diagnostic
section of the questionnaire. For the current survey, we used the
validated PAANS epilepsy screening questionnaire [4], and the survey
investigators underwent speciﬁc training in epilepsy. The questionnaire
was overseen by the project researcher and representatives of the
Ministry of Health andWHO. In fact, 42 of the 56 patients subsequently
conﬁrmed as having epilepsy had already been diagnosed with the dis-
ease, and only 14 new cases were identiﬁed in the survey. Our survey
also included people in urban regions where there is a higher level
of health education and awareness compared with rural regions,
which can facilitate the reporting of the disease. These observations
underscore the robustness of our study.
The high prevalence may be confounded by the lack of additional
diagnostic tools; indeed, lack of EEG was one of the main limitations
of this study. However, in their analysis of epilepsy surveys in
Sub-Saharan Africa, Paul et al. note that diagnosis should be conﬁrmed
by a HCP with expertise in epilepsy, using available medical history,
seizure description, and neurologic examination and that lack of
diagnostic instruments should not preclude the diagnosis of epilepsy
[7]. The diagnosis of the epileptic nature of a seizure can be based on
the description of the episode by the patient and witnesses and may
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brain scan by magnetic resonance imaging or an EEG recording should
not be used as screening tests owing to the presence of both false posi-
tives andnegatives; they should only beused to corroborate clinical sus-
picion [10]. To conﬁrm the diagnosis of epilepsy in our survey, patients
who had a positive screen underwent a clinical examination by a physi-
cian and a detailed historywas taken not only from the patients but also
from their family, caregivers, and friends.Witness descriptions areman-
datory for diagnostic purposes as they are more informative than the
patients', given seizure-related loss of awareness, confusion, or amnesia
[10].
It has been proposed thatwhile door-to-door studies are considered
to be the best available method for obtaining disease prevalence data,
they are unlikely to recognize all forms of epilepsy, but rather only the
most dramatic cases, and could, therefore, underestimate the true
prevalence [7]. In the case of a study conducted in Benin, the prevalence
was estimated to be 10.2% based on the results of a door-to-door survey
and 38% based on a capture–recapture method [11]. After an 18-month
follow-up during which health-care professionals, members of the
general population, and village leaders in the study area were asked to
identify suspected cases of epilepsy, the ﬁnal prevalence was estimated
to be 12% based on the combination of methods [11].
The majority (70%) of people with epilepsy in our survey reported
that they experienced generalized tonic–clonic seizures. Given limited
diagnostic facilities, a clear distinction could not be made in all cases.
Nonetheless, the predominance of generalized tonic–clonic seizures
has been reported in many other studies from Sub-Saharan Africa,
notably because such seizures are more easily identiﬁable compared
with other seizure types [5]. Use of EEG or scanning techniques could
provide different results. In a recent study from Tanzania, 291 people
with active epilepsy were offered investigation with a CT scan and
EEG, the results of which were reviewed by neurologists in the UK
[12]. At 71.5%, the predominant seizure type was found to be focal
onset. In a survey from Cameroon, 52.6% of the cases had been classiﬁed
as generalized, and 47.4% had been classiﬁed as focal epilepsy; after EEG
investigation, generalized seizures were conﬁrmed in 35.3% of the cases
and focal in 64.7% [6]. However, according to the ILAE guidelines for
epidemiological studies, EEG is not necessarily required for this
classiﬁcation [13].
In a substantial proportion of cases (36%) in our study, the onset of
epilepsy was reported to be before the age of 2 years, with a further
13% reporting onset before 6 years of age. Young onset, perinatal com-
plications, and premature encephalitis are all associated predominantly
with primary generalized seizures. Indeed, patient histories revealed
that family history of epilepsy, mother taking medication during
pregnancy, and premature birth were signiﬁcant etiological factors
associated with epilepsy, as well as diseases such as encephalitis and
severe measles; contact with dogs, cats, and pigs; head trauma with
loss of consciousness; and prolonged posttraumatic coma. The reported
potential causes of epilepsy are also in linewith theﬁndings froma large
study in Kenya, South Africa, Tanzania, Uganda, and Ghana [8].
A family history of febrile or nonfebrile convulsions and previous
head injury in adults were important preventable factors. In children,
perinatal events and their mother being a widow were possible risk
factors [14]. With regard to symptomatic epilepsy, potential causes of
epilepsy mentioned most frequently by respondents were obstructed
labor with fetal distress, serious childhood illness, and head trauma.
The most common childhood diseases were meningitis, measles, and
malaria. Head traumawasmost commonly reported as the consequence
of road accidents, blows to the head, and occupational accidents.
Infectious diseases caused by close contact with certain animals are
also important preventable causes of epilepsy. Recent evidence suggests
that neurocysticercosis is associated with a considerable proportion of
late-onset epilepsy in southern Rwanda [15]. Indeed, contact with
pigs, the intermediate host of the causative agent Taenia solium, was
one of the etiological factors identiﬁed in the survey. Humantoxocariasis caused by the larval stages of Toxocara canis and Toxocara
cati, the common roundwormof dogs and cats, respectively, is also asso-
ciated with epilepsy [16]. A signiﬁcant association between toxocariasis
and epilepsy was observed in neighboring Burundi [17]; results of our
survey suggest an association in Rwanda, which requires conﬁrmation
through additional research. Results of a meta-analysis of eight studies
from west (Benin and Nigeria), central (Cameroon and Central African
Republic), and east Africa (Uganda, Tanzania, and Burundi) also sug-
gested an association between epilepsy and onchocerciasis [18]; how-
ever, an association was not found in another study conducted in
Tanzania [19].
Our study is limited by recall and other social biases inherent to
surveys. Causative factors associated with epilepsy were evaluated
based on self-reported data using questionnaires, whichmay be subject
to recall bias and variability in the interpretation of questions. Further-
more, given the retrospective cross-sectional design of the survey, as
well as the absence of EEG and other diagnostic tests to corroborate
the self-reported ﬁndings, ﬁrm conclusions on the association between
the causative factors and epilepsy cannot be drawn.
The treatment gap of 68% in our survey while high is relatively
similar to those reported from recent studies across Sub-Saharan
Africa, notably 70% in Kenya [14] and 76% in Southeast Nigeria [20].
In a study from Tanzania, the treatment gap was 76%, rising to 86%
among patients with active epilepsy [21]. In another study from
Tanzania, the treatment gap was reported to be 95%; however, this
was in rural areas only [22]. Once again, it is important to reiterate
that the 68% treatment gap was noted in 2005; given the measures
described in Section 4.2, the current treatment gap is likely to be
substantially smaller.
The predominant reasons explaining the treatment gap not only in
Rwanda but also in other low-income countries are lack of resources,
whether low supplies and high cost of drugs or lack of adequately
trained HCPs [23–25]. Only 16% of the patients in our survey were
receiving AEDs, and, of these, only 49% took them on a regular basis.
The main reasons for not taking AEDs regularly were lack of funds
(56%) and unavailability of drugs (22%). Another important reason for
the treatment gap is that many individuals with epilepsy do not seek
treatment, since they may not recognize that treatment can help or
they are prevented from doing so in light of the substantial stigma
associated with the disease [24,25]. Indeed, epilepsy was associated
with signiﬁcant stigma in our survey (see below). Traditional beliefs in
the cause of epilepsy leadmany to seek relief from traditional remedies.
In Sub-Saharan Africa, as in many other poor regions, there is heavy
reliance on traditional healers for health-care needs, and people with
epilepsy have almost always sought care from healers before they are
seen byHCPs [26]. In our survey, 26% of the patients had orwere receiv-
ing some form of traditional treatment, whether oral remedies, scariﬁ-
cation or prayers and incantations. While many (52%) of them did not
consider these interventions effective, themajority (65%) of their family
members did. These observations suggest that the treatment gap could
be reduced substantially by ensuring adequate supplies of AEDs and ed-
ucational initiatives to change attitudes to epilepsy, thereby reducing
the stigma of epilepsy, which is a powerful barrier to effective care.
As noted above, the results of our survey unearthed substantial stig-
ma associated with epilepsy, similar to observations in other countries
in Sub-Saharan Africa. Epilepsy-associated stigma has been described
as a devastating burden to people with epilepsy in Sub-Saharan Africa,
with traditional healers identiﬁed as key ﬁgures in perpetuating the
stigma [26]. However, in a survey of traditional healers in Cameroon,
despite certain negative practices and attitudes, the majority reported
that they would readily refer a patient to the hospital [27]. The authors
suggest that collaboration between modern and traditional health-care
systems to bridge the epilepsy treatment gap is possible.
The majority (84%) of respondents in our survey expressed a fear of
epilepsy, while also revealing some understanding of the causes of epi-
lepsy, with 45% indicating that epilepsy was due to brain infection and
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Some respondents also thought that epilepsy was due to evil spirits,
casting of an evil spell, or evil thoughts. A similar supernatural and
scientiﬁc divide was noted in a study conducted in Tanzania; 46.7% of
the respondents thought that epilepsy was due to supernatural causes,
while 51.5% assumed that epilepsy is a neurological condition or is
inherited [28]. These observations indicate a gradual shift in the under-
standing and awareness of epilepsy, in that while attitudes may be
changing, traditional beliefs are deeply entrenched, and educational
initiatives are necessary. Indeed, despite some awareness of the causes
of epilepsy, many respondents reported that people with epilepsy
should not be entitled to schooling, to work, to the use of public places,
or to marriage. Half the respondents also believed that epilepsy was
untreatable, and 40% thought that it was a transmissible disease.
Epilepsy has also been reported to be a contagious disease by 41% of
people in Tanzania and 35% in Senegal [29,30].
4.2. Consequences of the survey ﬁndings— initiatives to combat epilepsy in
Rwanda
Following the ﬁrst disclosure of the results of this survey to the
Rwandan government in 2005, numerous actions were taken to in-
crease awareness of epilepsy, to reduce the stigma associated with the
disease and to close the treatment gap. The initiatives have been carried
out by different stakeholders, such as the Rwandan government, several
nongovernmental organizations (NGOs), and personal commitment of
individuals and funded or coordinated by bilateral or multilateral
developmental sponsors.
Among the ﬁrst of actions of the Rwandan government was to in-
clude the diagnosis and treatment of epilepsy in the minimal activity
package of primary health-care centers, as well as to develop treatment
guidelines. This was followed by ensuring availability of classic AEDs
(carbamazepine, phenobarbital, phenytoin, and valproate) in the
central pharmacy in Rwanda and access to phenobarbital in primary
health-care centers. Other short- and medium-term goals included
organizing educational seminars for HCPs, strengthening existing
neuropsychiatric facilities in the reference center in Kigali and the two
centers outside Kigali, and making EEG available in neuropsychiatric
reference centers. The ministry of health has developed and validated
a national strategic plan for mental health, which also includes epilepsy.
A more comprehensive action plan on nontransmissible chronic
diseases – diabetes, asthma, epilepsy, mental illnesses, and stroke – is
under development.
Following the survey, Handicap International, an independent NGO,
developed and implemented a vertically integrated epilepsy program
between 2008 and 2012 in four districts: two in the west, one in the
south, and one in the east of Rwanda [31]. The objectives of this program
were to overcome stigma by changing the attitude of the community
towards epilepsy and changing the perception of people with epilepsy
regarding self-esteem and treatment adherence. This was achieved
through training of volunteers within the community by raising
community inﬂuencers' awareness and providing psychological and edu-
cation support to patients and caregivers. Psychoeducational groupswere
also set up to encourage economic inclusion and to generate income.
Between 2008 and 2012, 6330 people with epilepsy have been iden-
tiﬁed in the four districts, with 2314 currently undermedical treatment.
A total of 460 health-care professionals have been trained, and 415
traditional healers and 563 religious leaders have been educated on
epilepsy and its management. Importantly, 931 children with epilepsy
have been integrated into regular primary schools.
The Rwandan League Against Epilepsy (RLAE) was created in 2009,
subsequently becoming the local chapter of the ILAE in 2013 [32]. The
initial objectives of the RLAE were identiﬁed as cascading centrally
available resources to the districts, providing educational information
to the general public about epilepsy, and strengthening capacities at
the primary care level. The RLAE currently consists of 41 members,including physicians, nurses, and people with epilepsy and their fami-
lies, who are closely involved in the development of programs to raise
awareness about epilepsy and the ﬁght against social exclusion of
people with epilepsy.
In 2012, the RLAE set up an ‘educational caravane’ in collaboration
with Fracarita (http://www.fracarita-belgium.org/) – a Belgian NGO –
and with the hospital of Ndera, Kigali. The aim of the caravane, which
consists of a group of medical staff from the Ndera hospital, is to build ca-
pacity for the diagnosis and treatment of individuals with epilepsy in the
Northern province. Physicians and nurses from district hospitals (N =
156) and primary care centers (N= 79) were trained in (differential) di-
agnosis of epilepsy, initiation of treatment, and identiﬁcation of patients
requiring referral to secondary or tertiary centers. Future initiatives aim
to include rural HCPs to ensure identiﬁcation of cases in more remote
areas of the country.
It is very encouraging to observe the impactful consequences of the
initial epidemiological research, whichwill ultimately improve the lives
of patientswith epilepsy in Rwanda. Continued efforts are needed to de-
velop capacities of HCPs and AED access programs; to raise awareness
within the community; to educate people with epilepsy, their
caregivers, and the whole community; and to eliminate the root causes
of stigma.5. Conclusion
Based on the results of this survey conducted in 2005, the prevalence
of epilepsy in Rwanda prevalence was found to be 49 per 1000 people,
which ranks among the highest in Sub-Saharan Africa. Living with epi-
lepsy was associated heavily with stigma, and a signiﬁcant treatment
gap (68%) was identiﬁed. Following this study, actions have been
taken by the Rwandan government, the RLAE, and several NGOs to
increase awareness about epilepsy and to close the treatment gap.
While much has been accomplished in a relatively short period of
time, continued efforts are needed to ensure that the momentum is
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